Hims & Hers stock jumps 6.76% after commitment to cheaper weight loss drugs fight

From Yahoo Finance: 2025-06-28 10:25:00

Hims & Hers Health, Inc. (NYSE:HIMS) stock soared 6.76% as CEO reaffirmed commitment to offering cheaper GLP-1 weight-loss drugs after partnership termination with Novo Nordisk, emphasizing customer advocacy. Novo Nordisk accused HIMS of violating laws by mass-selling compounded drugs under false pretenses, risking patient safety.

CEO Andrew Dudum of Hims & Hers Health, Inc. (NYSE:HIMS) stands firm against Novo Nordisk’s allegations, vowing to fight for customers despite partnership termination due to alleged deceptive marketing practices. The company remains focused on providing affordable medication options for consumers.

Investors celebrate as Hims & Hers (HIMS) stock rises after CEO’s declaration to continue offering cost-effective weight-loss drugs, following severed ties with Novo Nordisk. The company’s dedication to customer advocacy and commitment to affordable healthcare options drive its ongoing success in the market.

Read more: Hims & Hers (HIMS) Jumps 6.76% Anew as Investors Cheer Weight Loss Drug Fight